Esperion Therapeutics, Inc. (NASDAQ:ESPR) Shares Sold by Indaba Capital Management L.P.

Indaba Capital Management L.P. decreased its position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 91.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,000,000 shares of the biopharmaceutical company's stock after selling 30,750,000 shares during the quarter. Esperion Therapeutics makes up approximately 3.2% of Indaba Capital Management L.P.'s holdings, making the stock its 10th largest holding. Indaba Capital Management L.P. owned about 1.52% of Esperion Therapeutics worth $6,600,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in ESPR. Cibc World Markets Corp acquired a new position in Esperion Therapeutics during the 4th quarter valued at about $39,000. SJS Investment Consulting Inc. acquired a new position in Esperion Therapeutics in the fourth quarter valued at approximately $55,000. J.W. Cole Advisors Inc. bought a new position in Esperion Therapeutics in the fourth quarter valued at approximately $66,000. Foundations Investment Advisors LLC grew its holdings in Esperion Therapeutics by 48.6% during the 4th quarter. Foundations Investment Advisors LLC now owns 30,172 shares of the biopharmaceutical company's stock worth $66,000 after acquiring an additional 9,872 shares during the period. Finally, SLT Holdings LLC bought a new stake in shares of Esperion Therapeutics during the 4th quarter valued at $66,000. Institutional investors own 47.39% of the company's stock.

Esperion Therapeutics Stock Performance

NASDAQ ESPR traded up $0.11 during trading hours on Friday, reaching $1.09. 5,542,466 shares of the company's stock were exchanged, compared to its average volume of 5,675,294. The company has a market capitalization of $215.98 million, a price-to-earnings ratio of -1.70 and a beta of 0.75. The company's 50-day moving average is $1.31 and its two-hundred day moving average is $1.92. Esperion Therapeutics, Inc. has a one year low of $0.82 and a one year high of $3.94.

Analyst Ratings Changes

Several research analysts have recently issued reports on ESPR shares. The Goldman Sachs Group reduced their price target on Esperion Therapeutics from $4.00 to $3.00 and set a "neutral" rating on the stock in a research report on Thursday, April 17th. HC Wainwright restated a "buy" rating and set a $16.00 target price on shares of Esperion Therapeutics in a research report on Friday, April 25th. JMP Securities reiterated a "market outperform" rating and issued a $4.00 price target (down from $7.00) on shares of Esperion Therapeutics in a research report on Tuesday, February 11th. Finally, Needham & Company LLC restated a "buy" rating and set a $5.00 price objective on shares of Esperion Therapeutics in a report on Friday, April 25th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Esperion Therapeutics has an average rating of "Hold" and an average target price of $6.42.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.